Citations

Clear

334 citation(s) found for "Jacobs, C".

Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer
Burke, Olivia , Jacobs, Jeremy W. , Rinder, Henry M. , Villalba, Cristina A. Figueroa , Lee, Edward S. , Campos, Juan J Silva, Abels, Elizabeth , Yurtsever, Nalan, Yurtsever, Nalan , Lee, Edward S , Jacobs, Jeremy W , Yurtsever, Nalan , Burke, Olivia, Tormey, Christopher A.

Mayo Clinic

Laboratory Medicine | December 24, 2023 | Volume: 55 | Issue: 4 | Pages: 520-523

10.1093/labmed/lmad107 | PMID 38142129 Get It

Abstract The Heidenhain variant of Creutzfeld-Jakob disease (CJD) is a rare form that initially presents with visual disturbances. In early stages, the presentation can mimic neuromyelitis optica spectrum disorders (NMOSD) and lead to unnecessary treatment modalities. Herein, we describe a case of a 66-year-old man who presented with bilateral vision loss and retro-orbital discomfort. In addition to immunosuppressive therapy, he received 4 rounds of therapeutic plasma exchange after his preliminary diagnosis of NMOSD. We were surprised to note that his condition did not show improvement but deteriorated, with severe neurocognitive symptoms. Eventually, CJD was suspected, and real-time quaking-induced conversion (RT-QuIC) was performed. By the time the diagnosis of Heidenhain variant of CJD was confirmed, the patient was discharged to hospice care and died shortly after.
The effect of frequency (64–498 MHz) on specific absorption rate adjacent to metallic orthopedic screws in MRI: A numerical simulation study
Jacobs, Paul , Fagan, Andrew

Mayo Clinic

Medical Physics | December 20, 2023 | Volume: 51 | Issue: 2 | Pages: 1074-1082

10.1002/mp.16902 | PMID 38116822 Get It

AbstractBackgroundThe imaging of patients with implanted electrically‐conductive devices via magnetic resonance imaging at ultra‐high fields is hampered by uncertainties relating to the potential for inducing tissue heating adjacent to the implant due to coupling of energy from the incident electromagnetic field into the implant. Existing data in the peer‐reviewed literature of comparisons across field strengths of tissue heating and its surrogate, the specific absorption rate (SAR), is scarce and contradictory, leading to further doubts pertaining to the safety of imaging patients with such devices.PurposeThe radiofrequency‐induced SAR adjacent to orthopedic screws of varying length and at frequencies of 64 to 498 MHz was investigated via full‐wave electromagnetic simulations, to provide an accurate comparison of SAR across MRI field strengths.MethodsDipole antennas were used for RF transmission to achieve a uniform electric field tangential to the screws located 120 mm above the antenna midpoints, embedded in a bone‐mimicking material. The input power to the antennas was constrained to achieve the following targets without the screw present: (i) E = 100 V/m, (ii) B1+ = 2 μT, and (iii) global‐average‐SAR = 3.2 W/kg. Simulations were performed with a spatial resolution of 0.2 mm in the volume surrounding the screws, resulting in 76–137 MCells, noting the maximum 1 g‐averaged SAR value in each case. Simulations were repeated at 128 and 297 MHz for screws embedded in muscle tissue.ResultsThe peak SAR, occurring at the resonant screw length, substantially increased as the frequency decreased when the input power to the dipole antenna was constrained to achieve constant electric field in background tissue at the screws’ locations. A similar pattern was observed when constraining input power to achieve constant B1+ and global‐average‐SAR. The dielectric properties of the tissue in which the screws were embedded dominated the SAR comparisons between 297 and 128 MHz.ConclusionsThe study design allowed for a direct comparison to be performed of SAR across frequencies and implant lengths without the confounding effect of variable incident electric field. Lower frequencies produced substantially larger SAR values for implants approaching the resonant length for the worst‐case uniform incident electric field along the screws’ length. The data may inform risk‐benefit assessments for imaging patients with orthopedic implants at the new clinical field strength of 7 Tesla.
Abstract 18324: Artificial Intelligence ECG as a Novel Method to Detect Cardiotoxicity After Anthracyclines
Jacobs, J. , Greason, Grace , Willems, Rik , Janssens, Stefan , Voigt, Jens‐Uwe , Friedman, Paul A. , Aelst, Lucas Van , Herrmann, Joerg , Jacobs, Johanna E J , Van Aelst, Lucas N L , Voigt, Jens-Uwe , Wildiers, Hans , Noseworthy, Peter A. , López-Jiménez, Francisco , Vandenberk, Bert , Attia, Zachi I.

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18324 Get It

Introduction: Cardiotoxicity is a serious side effect of anthracycline treatment, most commonly manifesting as a reduction in left ventricular ejection fraction (LVEF) on cardiac imaging. Cost-effective alternatives to cardiac imaging are currently not available. Artificial intelligence (AI) models have been developed to detect a reduced LVEF from 12-lead electrocardiograms (ECGs) in the general population. Hypothesis: AI-ECG model can detect a reduced LVEF after anthracycline therapy (i.e. cardiotoxicity). Methods: We included an unbiased oncological population of 989 female breast cancer patients receiving (neo)adjuvant anthracycline chemotherapy. Average follow-up time was 9.83±4.2 years. Patients with incomplete transthoracic echocardiography (TTE) data, HER-2-directed therapy, significant comorbidities, upfront metastatic disease, second primary malignancy or pre-existing cardiovascular disease were excluded from the analyses. Patients with LVEF decline for reasons other than anthracycline-induced cardiotoxicity were also excluded. Primary readout was the diagnostic performance of AI-ECG by area under the curve (AUC) for various levels of LVEF <50%. Results: Using 1,877 ECGs from 703 unique patients, the AI-ECG model detected an LVEF <50% and ≤35% after anthracycline therapy with an AUC of 0.93 and 0.94, respectively. Conclusions: These data support the use of AI-ECG for cardiomyopathy (cardiotoxicity) screening after anthracycline-based chemotherapy. This technology could serve as a gatekeeper to more costly testing and could enable patients to monitor themselves over long periods of time.
Abstract 16570: Benchmarking Risk-Adjusted Outcomes in Congenital Heart Surgery
Subramanyan, Ram Kumar, Thibault, Dylan, O’Brien, Sean M. , Shahian, David M. , Bacha, Emile , Badhwar, Vinay , Caldarone, C.A., Fernández, Félix G. , Pasquali, Sara K. , Rainey, Tabitha, Romano, Jennifer C., Shashidharan, Subhadra, Tweddell, James S., Mayer, John E. , Gaynor, J. William , Dearani, Joseph A. , Jacobs, Jeffrey P. , Overman, David M.

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.16570 Get It

Background: Robust models exist to predict risk-adjusted mortality following congenital heart surgery. It is known that underlying diagnosis modifies predicted risk of operations, and institution-level outcomes vary based on their unique case mix. We therefore evaluated risk-adjusted outcomes for a subset of diagnosis-procedure (D-P) combinations within the Society of Thoracic Surgeons' (STS) congenital heart surgery database (CHSD). Methods: A clinician panel identified the most frequently encountered D-P combinations in CHSD between 07/2017 and 06/2021. Candidate modeling techniques were compared in a random 80% development cohort. Model performance was assessed using internal and cross-validation calibration, discrimination plots and optimism adjusted C-statistics. The final selected model was evaluated in the 20% validation sample. Results: The chosen subset of D-P combinations represented 45,384 of 87,589 (52%) unique episodes of surgical care in CHSD during this time-period. The development cohort (36,350 episodes) had 1.8% mortality (667 deaths). All candidate models had excellent discrimination with C-statistics ranging from 0.862 to 0.876. The model with the best combination of discrimination, calibration, and clinical face validity was a modified version of the current STS mortality risk model. This version included all current risk model variables with the addition of indicator variables for D-P combinations. In the 20% validation sample (9,034 episodes), this model was well calibrated (Figure) and had excellent discrimination (C = 0.879). Conclusion: We describe a cohort of D-P combinations widely encountered in the STS CHSD. Further, we refined the existing STS CHSD risk model for application to these D-P dyads to derive empirical risk-adjusted benchmark outcomes. This approach will benefit quality improvement efforts at an institutional level and may have implications for publicly reporting congenital heart surgery outcomes.
All that hemolyzes with complement is not cold agglutinin syndrome
Jacobs, Jeremy W. , Adkins, Brian D. , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Booth, Garrett S.

Mayo Clinic

Revista Paulista de Pediatria | December 18, 2023 | Volume: 42 | Issue: No issue available | Pages: No page available

10.1590/1984-0462/2024/42/2023144 | PMID 38126441 Get It

Causes of death among people with myelomeningocele: A multi-institutional 47-year retrospective study
Szymanski, Konrad M. , Adams, Cyrus , Austin, Paul F. , Castillo, Heidi , Castillo, Jonathan , Chu, David I. , Estrada, Carlos R. , Fascelli, Michele , Frimberger, Dominic, Gargollo, Patricio C. , Hamdan, Dawud , Hecht, Sarah L. , Hopson, Betsy , Husmann, Douglas A. , Jacobs, Micah A. , MacNeily, Andrew E. , McLeod, Daryl J. , Meyer, Theresa , Misseri, Rosalia , O’Neil, Joseph, Rove, Kyle O. , Sawin, Kathleen J. , Schlomer, Bruce J., Shamblin, Isaac , Sherlock, Rebecca , Slobodov, Gennady , Stout, Jennifer, Tanaka, Stacy T. , Weiß, Dana , Wiener, John S. , Wood, Hadley , Yerkes, Elizabeth B. , Blount, Jeffrey P. , Alkawaldeh, Mohammad Y. , Bowman, Robin M. , Metcalfe, Peter , Rensing, Adam J. , Routh, Jonathan C.

Mayo Clinic

Journal of Pediatric Rehabilitation Medicine | December 8, 2023 | Volume: 16 | Issue: 4 | Pages: 605-619

10.3233/prm-220086 | PMID 38073338 Get It

PURPOSE: This study aimed to analyze organ system-based causes and non-organ system-based mechanisms of death (COD, MOD) in people with myelomeningocele (MMC), comparing urological to other COD. METHODS: A retrospective review was performed of 16 institutions in Canada/United States of non-random convenience sample of people with MMC (born > = 1972) using non-parametric statistics. RESULTS: Of 293 deaths (89% shunted hydrocephalus), 12% occurred in infancy, 35% in childhood, and 53% in adulthood (documented COD: 74%). For 261 shunted individuals, leading COD were neurological (21%) and pulmonary (17%), and leading MOD were infections (34%, including shunt infections: 4%) and non-infectious shunt malfunctions (14%). For 32 unshunted individuals, leading COD were pulmonary (34%) and cardiovascular (13%), and leading MOD were infections (38%) and non-infectious pulmonary (16%). COD and MOD varied by shunt status and age (p < = 0.04), not ambulation or birthyear (p > = 0.16). Urology-related deaths (urosepsis, renal failure, hematuria, bladder perforation/cancer: 10%) were more likely in females (p = 0.01), independent of age, shunt, or ambulatory status (p > = 0.40). COD/MOD were independent of bladder augmentation (p = >0.11). Unexplained deaths while asleep (4%) were independent of age, shunt status, and epilepsy (p >= 0.47). CONCLUSION: COD varied by shunt status. Leading MOD were infectious. Urology-related deaths (10%) were independent of shunt status; 26% of COD were unknown. Life-long multidisciplinary care and accurate mortality documentation are needed.
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
Jain, Michael D. , Jacobs, Miriam T. , Gao, Feng , Nastoupil, Loretta J. , Spiegel, Jay Y. , Dahiya, Saurabh , Lunning, Matthew A. , Lekakis, Lazaros J. , Deol, Abhinav , Sehgal, Alison R. , Hill, Brian T. , Rapoport, Aaron P. , Neelapu, Sattva S. , Dahiya, Saurabh , Oluwole, Olalekan O , McGuirk, Joseph , Deol, Abhinav , Goy, Andre Henri , Andreadis, Charalambos Babis , Munoz, Javier L , Bennani, N Nora , Vose, Julie , Miklos, David B , Neelapu, Sattva S , Ghobadi, Armin , Jain, Michael D , Nastoupil, Loretta J , Jacobs, Miriam T , Lin, Yi , Reagan, Patrick Michael , Oluwole, Olalekan O. , McGuirk, Joseph P. , Muñoz, Javier , Chavez, Julio C , Bennani, N. Nora , Vose, Julie M. , Miklos, David B. , Locke, Frederick L. , Ghobadi, Armin

Mayo Clinic

Blood Advances | December 5, 2023 | Volume: 8 | Issue: 4 | Pages: 1042-1050

10.1182/bloodadvances.2023011489 | PMID 38051550 Get It

Abstract During the manufacturing period of autologous chimeric antigen receptor (CAR) T-cell therapy, patients may experience a decline in their condition due to cancer progression. In this study, we investigated the impact of bridging therapy (BT) on the outcome of patients with relapsed/refractory large B-cell lymphoma who received antilymphoma treatment between leukapheresis and axicabtagene ciloleucel (axi-cel) infusion. We conducted our analysis using data from the multicenter US Lymphoma CAR-T Consortium, with a median follow-up of 33 months (range, 4.3-42.1). Out of the 298 patients who underwent leukapheresis, 275 patients received axi-cel. A total 52% of patients (n = 143) who received BT had a higher baseline risk profile than patients who did not receive BT, and these patients, as a group, had inferior outcomes compared with those who did not receive BT. However, after propensity score matching between the 2 groups, there were no statistically significant differences in overall response rate (77% vs 87%; P = .13), complete response rate (58% vs 70%; P = .1), progression-free survival (hazard ratio [HR], 1.25; P = .23), and overall survival (HR, 1.39; P=.09) between the BT group and the no-BT group, respectively. Analyzing the effects of BT in the whole cohort that underwent leukapheresis regardless of receiving axi-cel (intention-to-treat analysis) showed similar results. Radiation BT resulted in outcomes similar to those observed with nonradiation BT. Our findings suggest that BT may be safe without a significant impact on long-term survival for patients who require disease stabilization during the manufacturing period. Moreover, our results suggest that there is no clear advantage to using radiation-based BT over nonradiation-based BT.